var data={"title":"Guaifenesin and pseudoephedrine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Guaifenesin and pseudoephedrine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6291?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=guaifenesin-and-pseudoephedrine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Guaifenesin and pseudoephedrine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177863\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aldex GS [OTC];</li>\n      <li>Altarussin-PE [OTC];</li>\n      <li>Congestac [OTC] [DSC];</li>\n      <li>Entex T [OTC];</li>\n      <li>ExeFen-IR [OTC] [DSC];</li>\n      <li>GoodSense Mucus-D [OTC];</li>\n      <li>Mucinex D Maximum Strength [OTC];</li>\n      <li>Mucinex D [OTC];</li>\n      <li>Poly-Vent IR [OTC];</li>\n      <li>Refenesen Plus [OTC] [DSC];</li>\n      <li>Respaire-30 [OTC];</li>\n      <li>Rydex G [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177864\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Contac Cold-Chest Congestion, Non Drowsy, Regular Strength;</li>\n      <li>Entex LA;</li>\n      <li>Novahistex Expectorant with Decongestant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177879\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha-/Beta- Agonist;</li>\n      <li>\n        Expectorant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177867\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Also refer to specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Expectorant/decongestant:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (Congestac): Guaifenesin 400 mg/pseudoephedrine 60 mg every 4 to 6 hours (maximum: Guaifenesin 1,600 mg/pseudoephedrine 240 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (Entex T): Guaifenesin 375 mg/pseudoephedrine 60 mg every 4 hours (maximum: Guaifenesin 1,500 mg/pseudoephedrine 240 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, extended release (Mucinex D, Mucinex D Maximum Strength): Guaifenesin 1,200 mg/pseudoephedrine 120 mg every 12 hours (maximum: Guaifenesin 2,400 mg/pseudoephedrine 240 mg/24 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177875\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Also refer to specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Expectorant/decongestant:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children 6 to 11  years:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet (Congestac): Guaifenesin 200 mg/pseudoephedrine 30 mg every 4 to 6 hours (maximum: Guaifenesin 800 mg/pseudoephedrine 120 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet (Entex T): Guaifenesin 187.5 mg/pseudoephedrine 30 mg every 4 hours (maximum: Guaifenesin 750 mg/pseudoephedrine 120 mg/24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children &ge;12 years and Adolescents:</i> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177868\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50049059\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50049060\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177851\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respaire-30: Guaifenesin 150 mg and pseudoephedrine hydrochloride 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Syrup, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Altarussin-PE: Guaifenesin 100 mg and pseudoephedrine hydrochloride 30 mg per 5 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aldex GS: Guaifenesin 190 mg and pseudoephedrine hydrochloride 30 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Congestac: Guaifenesin 400 mg and pseudoephedrine hydrochloride 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Entex T: Guaifenesin 375 mg and pseudoephedrine hydrochloride 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ExeFen-IR: Guaifenesin 400 mg and pseudoephedrine hydrochloride 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Poly-Vent IR: Guaifenesin 380 mg and pseudoephedrine hydrochloride 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Refenesen Plus: Guaifenesin 400 mg and pseudoephedrine hydrochloride 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rydex G: Guaifenesin 398 mg and pseudoephedrine hydrochloride 38.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet Extended Release 12 Hour, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GoodSense Mucus-D: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex D: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mucinex D Maximum Strength: Guaifenesin 1200 mg and pseudoephedrine hydrochloride 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Guaifenesin 600 mg and pseudoephedrine hydrochloride 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177840\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177854\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Do not crush, chew, or break extended release formulations. May interfere with sleep; administering some products a few hours before bedtime may help minimize insomnia. Take with full glass of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177853\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Expectorant/decongestant:</b> Temporary relief of nasal/sinus congestion and sinus pressure by promoting nasal/sinus drainage associated with common cold, hay fever, or upper respiratory allergies; loosens mucus and thins bronchial secretions making coughs more productive; temporararily restores freer breathing through the nose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177886\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Entex may be confused with Tenex </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Entex LA brand name represents a different product in the U.S. than it does in Canada. In the U.S., Entex LA contains guaifenesin and phenylephrine, while in Canada the product bearing this brand name contains guaifenesin and pseudoephedrine. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucinex D may be confused with Mucinex DM</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177846\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177857\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177843\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Safety and efficacy have not been established in children &lt;2 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299427\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177847\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8963&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<b> Exceptions: </b>Linezolid; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary Acidifying Agents: May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177859\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177860\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177856\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323175\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Respaire-30 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30-150 mg (100): $81.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Tusnel Pediatric Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5-50 mg/mL (60 mL): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Mucinex D Max Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120-1200 mg (24): $24.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Mucinex D Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60-600 mg (18): $11.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Pseudoephedrine-Guaifenesin ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60-600 mg (18): $10.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Entex T Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60-375 mg (100): $91.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Poly-Vent IR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60-380 mg (100): $73.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177861\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Guafedrin (AE, QA, SA);</li>\n      <li>Robitussin Chesty Cough with Congestion (MT);</li>\n      <li>Robitussin Plus (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Congestac (pseudoephedrine hydrochloride/guaifenesin tablet) [prescribing information]. Lenexa, KS: B.F. Ascher &amp; Co, Inc.; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Entex T (guaifenesin and pseudoephedrine hydrochloride tablet) [prescribing information]. Ridgeland, MS: WraSer Pharmaceuticals, LLC.; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mucinex D (guaifenesin and pseudoephedrine hydrochloride tablet, extended release) [prescribing information]. Parsippany, NJ: Reckitt Benckiser, LLC.; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mucinex D Maximum Strength (guaifenesin and pseudoephedrine hydrochloride tablet, extended release) [prescribing information]. Parsippany, NJ: Reckitt Benckiser, LLC.; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taverner D, Latte J. Nasal decongestants for the common cold. <i>Cochrane Database Syst Rev</i>. 2007;1:CD001953.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/guaifenesin-and-pseudoephedrine-drug-information/abstract-text/17253470/pubmed\" target=\"_blank\" id=\"17253470\">17253470</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8963 Version 98.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F177863\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F177864\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F177879\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177867\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F177875\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F177868\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50049059\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50049060\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F177851\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F177840\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F177854\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F177853\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F177886\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177846\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177857\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177843\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299427\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F177847\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F177859\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F177860\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F177856\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323175\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F177861\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8963|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=guaifenesin-and-pseudoephedrine-patient-drug-information\" class=\"drug drug_patient\">Guaifenesin and pseudoephedrine: Patient drug information</a></li></ul></div></div>","javascript":null}